Targeting of tumor cells by lymphocytes engineered to express chimeric receptor genes

Cancer Immunology, Immunotherapy

Volumn 53, Issue 10, 2004, Pages 893-903

  Baxevanis, Constantin N ^a   Papamichai, Michael ^a  

^a SAINT SAVVAS HOSPITAL   (Greece)

Author keywords

Cancer immunotherapy; Chimeric antigen receptors; Costimulatory molecules; Single chain Fv; Tumor immunosurveillance

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CHIMERIC ANTIBODY; CHIMERIC MONOCLONAL ANTIBODY SINGLE CHAIN FV FRAGMENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2 ANTIBODY; GENE PRODUCT; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; LYMPHOCYTE ANTIGEN RECEPTOR; MONOCLONAL ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY IMMUNOGLOBULIN FC FRAGMENT GAMMA CHAIN FUSION PROTEIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY T LYMPHOCYTE RECEPTOR ZETA CHAIN FUSION PROTEIN; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR ZETA CHAIN; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ANTIGEN PRESENTING CELL; BINDING AFFINITY; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CELL ACTIVATION; CELL STRAIN NK 92; CELL STRUCTURE; CHIMERIC RECEPTOR GENE; CLINICAL TRIAL; CONFERENCE PAPER; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DRUG DESIGN; GENE FUSION; GENETIC ENGINEERING; GENETIC TRANSDUCTION; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOGLOBULIN GENE; LIGAND BINDING; LYMPHOKINE ACTIVATED KILLER CELL; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; RECEPTOR BINDING; RECEPTOR GENE; T LYMPHOCYTE; TARGET CELL; TUMOR CELL;

AMINO ACID MOTIFS; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; GENES, IMMUNOGLOBULIN; GENES, SYNTHETIC; HLA ANTIGENS; HUMANS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOTHERAPY, ADOPTIVE; KILLER CELLS, NATURAL; NEOPLASMS; PHOSPHORYLATION; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, CYTOTOXIC; TRANSDUCTION, GENETIC;

EID: 4744376594     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-004-0523-y     Document Type: Conference Paper

References (85)

1. Haynes NM, Trapani JA, Teng MWL, Jackson JT, Cerruti L, Jane SM, Kershaw MH, Smyth M, Darcy PK (2002) Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. Blood 100:3155
2. Browning M, Petronzelli F, Bicknell D, Krausa P, Rowan A, Touks S, Murray N, Bodmer J, Bodmer W (1996) Mechanisms of loss of HLA class I expression on colorectal tumor cells. Tissue Antigens 47:364
3. Garrido D, Ruiz-Cabello F, Cabrera T, Perez-Villar JJ, Lopez-Botet M, Duggaun-Keen M, Stern PL (1997) Implication for immunosurveillance of altered HLA class I phenotypes in human tumors. Immunol Today 18:89
4. Hui K, Grosveld F, Festenstein H (1984) Rejection of transplantable AKR leukemia cells following MHC DNA-mediated cell transformation. Nature 311:750
5. Hui K (1989) Re-expression of major histocompatibility complex (MHC) class I molecules on malignant tumor cells and its effect on host-tumor interaction. Bioessays 11:22
6. Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE (1994) Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin-2. J Natl Cancer Inst 86:1159
7. Stofer G, Goey SH, Batchelor D, Eggermont AD, Lamers C, Gratama JW, Bolhuis RCH (1992) EORTC genitourinary group monograph no. 11. In: Schroeder FH (ed) Recent progress in bladder and kidney cancer: treatment of disseminated renal cell cancer with combinations of interleukin-2, lymphokine-activated killer cells, and a-interferon. Wiley-Liss, New York, pp 225
8. Rosenberg SA (1992) The immunotherapy and gene therapy of cancer. J Clin Oncol 10:180
9. Baxevanis CN, Dedoussis GVZ, Papadopoulos NG, Missitzis I, Stathopoulos GP, Papamichail M (1994) Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer. Cancer 74:1275
10. Baxevanis CN, Papamichail M (1994) Characterization of the anti-tumor immune response in human cancers and strategies for immunotherapy. Crit Rev Oncol Hematol 16:157
11. Jain RK (1989) Delivery of novel therapeutic agents on tumors: physiological barriers and strategies. J Natl Cancer Inst 81:570
12. Blank-Voorthuis CJAC, Braakman E, Ronteltap CRM, Tilly BC, Sturm E, Warnaar SO, Bolhuis RLH (1993) Clustered CD3/TCR complexes do not transduce activation signals after bispecific monoclonal antibody-triggered lysis by CTL via CD3. J Immunol 151:2904
13. Lanzavecchia A, Scheidegger D (1987) The use of hybrid hybridomas to target human cytotoxic T lymphocytes. Eur J Immunol 17:105
14. Brocker T, Peter A, Traunecker A, Karjalainen K (1993) New simplified molecular design for functional T cell receptor. Eur J Immunol 23:1435
15. Eshhar Z, Waks T, Gross D, Schindler DG (1993) Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the γ or z subunits of the immunoglobuliln and T-cell receptors. Proc Natl Acad Sci U S A 90:720
16. Nolan KF, Yun CO, Akamatsu Y, Murphy JC, Leung SO, Beechamn EJ, Junghans RF (1999) Bypassing immunization: optimised design of "designer T cells" against carcinoembryonic antigen (CEA)-expressing tumors and lack of suppression of soluble CEA. Clin Cancer Res 5:3928
17. Kuwana Y, Asakura Y, Utsonomiya N, Nakanishi M, Arata Y, Itoh S, Nagase F, Kurosawa Y (1989) Expression of chimeric receptor composed of immunoglobuliln-derived V regions and T-cell receptor-derived C regions. Biochem Biophys Res Commun 149:960
18. Brocker T, Karjalainen K (1998) Adoptive tumor immunity mediated by lymphocytes bearing modified antigen-specific receptors. Adv Immunol 68:257
19. Eshhar Z (1997) Tumor-specific T-bodies: towards clinical application. Cancer Immunol Immunother 45:131
20. Irving BA, Weiss A (1991) The cytoplasmic domain of the T cell receptor ζ chain is sufficient to couple to receptor-associated signal transduction pathways. Cell 64:891
21. Letourneur F, Klausner RD (1991) T cell and basophile activation through the cytoplasmic tail of T-cell receptor ζ family proteins. Proc Natl Acad Sci U S A 88:8905
22. Romeo C, Seed B (1991) Cellular immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptides. Cell 64:1037
23. Alvarez-Vallina L (2001) Genetic approaches for antigen selective cell therapy. Curr Gene Ther 1:385
24. Alvarez-Vallina L, Hawkins RE (1996) Antigen-specific targeting of CD28-mediated T cell co-stimulation using chimeric single-chain antibody variable fragment-CD28 receptors. Eur J Immunol 26:2301
25. Roberts MR, Cooke KS, Tran AC, Smith KA, Lin WY, Wang M, Dull TJ, Farson D, Zsebo KM, Finer MH (1998) Antigen-specific cytolysis by neutrophils and NK cells expressing chimeric immune receptors bearing ζ or γ signaling domains. J Immunol 1:375
26. Hoogenboom HR, Marks JD, Griffiths AD, Winter G (1992) Building antibodies from their genes. Immunol Rev 130:41
27. Gritzapis AD, Mamalaki A, Kretsovali A, Papamatheakis J, Belimezi M, Perez SA, Baxevanis CN, Papamichail M (2003) Redirecting mouse T-hybridoma against tumor breast and ovarian carcinomas: in vivo activity against HER-2/neu expressing cancer cells. Br J Cancer 88:1292
28. Mamalaki A, Gritzapis AD, Kretsovali A, Belimezi M, Papamatheakis J, Perez SA, Pamamichail M, Baxevanis CN (2003) In vitro and in vivo antitumor activity of a mouse CTL hybridoma expressing chimeric receptors bearing the single chain Fv from HER-2/neu-specific antibody and the γ-chain from Fc (ζ)RI. Cancer Immunol Immunother 52:513
29. Moritz D, Groner B. (1995) A spacer region between the single chain antibody and the CD3ζ-chain domain of chimeric T cell receptor components is required for efficient ligand binding and signaling activity. Gene Ther 2:539
30. Hombach A, Wieczarkowiecz A, Marquardt T, Heuser C, Usai L, Pohl C, Seliger B, Abkau H (2001) Tumor-specific T cell activation by recombinant immunoreceptors: CD3ζ signaling and CD28 stimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD33 signaling receptor molecule. J Immunol 167:6123
31. Daeron M (1997) Fc receptor biology. Annu Rev Immunol 15:203
32. Klausner RD, Sauelson LE (1991) T cell antigen activation pathways: the tyrosine kinase connection. Cell 64:875
33. Quian D, Weiss A (1997) T cell antigen receptor signal transduction. Curr Opin Cell Biol 9:205
34. Wange RL, Samelson LE (1996) Compex complexes: signaling at the TCR. Immunity 5:197
35. Weiss A, Littman DR (1994) Signal transductin by lymphocyte antigen receptors. Cell 76:263
36. Zhang W, Sloan-Lancaster J, Kitchen J, Tribble RP, Samelson LE (1998) LAT: the zap-70 tyrosine kinase substrate that links T cell receptor to cellular activation. Cell 92:83
37. Weijtens MEM, Willemsen RA, Valerio D, Stam K, Bolhuis RLH (1996) Single chain Ig/γ gene-redirected human T lymphocytes produce cytokines, specifically lyse tumor cells, and recycle lytic capacity. J Immunol 157:836
38. Zoller KE, MacNeil IA, Bruppe JS (1997) Protein tyrosine kinases Syk and ZAP-70 display distinct requirements for Src family kinases in immune response receptor signal transduction. J Immunol 158:1650
39. Indik Z, Park JG, Hunter S, Schreiber AD (1995) The molecular dissection of Fcγ receptor mediated phagocytosis. Blood 86:4389
40. Wegener AK, Letourneur G (1992) The T cell receptor/CD3 complex is composed of at least two autonomous transduction molecules. Cell 68:83
41. Pawelec C, Zeuthen J, Kiessling R (1997) Escape from host-antitumor immunity. Crit Rev Oncog 8:111
42. Yun CO, Nolan KF, Beecham EJ, Reisfeld RA, Junghaus RP (2000) Targeting of T lymphocytes to melanoma cells through chimeric anti-GD3 immunoglobulin T-cell receptors. Neoplasia 2:449
43. Fitzer-Atlas CJ, Schindler DG, Waks T, Eshhar Z (1998) Harnessing Syk family tyrosine kinases as signaling domains for chimeric single chain of the variable domain receptors: optimal design for T cell activation. J Immunol 160:145
44. Altenschmidt U, Klundt E, Groner B (1997) Adoptive transfer of in vitro-targeted, activated T lymphocytes results in total tumor rejection. J Immunol 159:5509
45. Darcy PK, Haynes NM, Snook MB, Trapani JA, Cerruti L, Jane SM, Smyth MJ (2000) Redirected perforin-dependent lysis of colon carcinoma by ex vivo genetically engineered CTL. J Immunol 164:3705
46. Darcy PK, Kershaw MH, Trapani JA, Smyth MJ (1998) Expression in cytotoxic T lymphocytes of a single-chain anti-carcinoembryonic antigen-antibody. Redirected Fas ligand-mediated lysis of colon carcinoma. Eur J Immunol 28:1663
47. Nagayama H, Takahashi S, Takahashi T, Ogami K, Ikebuchi K, Tani T, Asano S (1999) IL-2/LAK therapy for refractory acute monoblastic leukemia relapsing after unrelated allogenic bone marrow transplantation. Bone Marrow Transplant 23:183
48. Moritz D, Wels W, Mattern J, Growe B (1994) Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells. Proc Natl Acad Sci U S A 91:4318
49. Wels W, Harworth I-M, Mueller M, Grower B, Hynes NE (1992) Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB2 receptor. Cancer Res 52:6310
50. Biever BE, Sleckman BP, Rarnofsky SE, Burakoff SJ (1989) The biologic roles of CD2, CD4 and CD8 in T-cell activation. Annu Rev Immunol 7:759
51. Janeway CA (1992) The T cell receptor as a multicomponent signalling machine: CD4/CD8 coreceptors and CD45 in T cell activation. Annu Rev Immunol 10:645
52. Alberoia-Ila J, Places J, Cantrell DA, Vives J, Lozano F (1992) Intracellular events involved in CD5-induced human T cell activation and proliferation. J Immunol 148:1287
53. Lenschow DJ, Walunas TL, Bluestone JA (1996) CD28/B7 system of T cell costimulation. Annu Rev Immunol 14:233
54. Vandenberghe P, Freeman GJ, Nadler LM, Fletcher MC, Kamoun M, Turka A, Ledbetter JA, Thompson CB, June CH (1992) Antibody and B7/BB1-mediated ligation of the CD28 receptor induces tyrosine phosphorylation in human T cells. J Exp Med 175:951-960
55. Harding FA, Allison JR (1993) CD28-B7 interactions allow the induction of CD8 + cytotoxic T lymphocytes in the absence of exogenous help. J Exp Med 177:1791
56. Rudd CE (1996) Upstream-downstream: CD28 cosignaling pathways and T Cell function. Immunity 4:527
57. Stein PA, Fraser JD, Weiss A (1994) The cytoplasmic domain of CD28 is both necessary and sufficient for costimulation of interleukin-2 secretion and association with phosphatidylinositol 3′ kinase. Mol Cell Biol 14:3392
58. Finney HM, Lawson ADG, Bebbington CR, Weir ANC (1998) Chimeric receptors providing both primary and costimuloatory signaling in T cells from a single gene product. J Immunol 161:2791
59. Maher J, Brentjens RJ, Gunset G, Riviere I, Sadelain M (2002) Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRJ/CD28 receptor. Nat Biotechnol 70
60. Bennett M (1987) Biology and genetics of hybrid resistance. Adv Immunol 41:333
61. Smyth MJ, Hayakawa Y, Takeda K, Yagita H (2002) New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Immunol 2:850
62. Rosenberg SA, Lotze MT, Yang JC, Topalian SL, Chang AE, Schwartzentruber DJ, Aebersold P, Leitman S, Linehan WM, Seip LA et al (1993) Prospective randomized trial of high-dose interleukin-2 alone or in combination with lymphokine-activated killer cells for the treatment of patients with advanced cancer J Natl Cancer Inst 85:622
63. Whiteside TL, Vujanovic NL, Herberman RB (1998) Natural killer cells and tumor therapy. Curr Top Microbiol Immunol 230:221
64. Tonn T, Becker S, Esser R, Schwabe D, Seifried E (2001) Cellular Immunotherapy of malignancies using the clonal natural killer cell line NK-92. J Hematother Stem Cell Res 10:535
65. Klingemann HG, Wang E, Maki GA (1996) A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from blood. Biol Blood Marrow Transplant 2:68
66. Gong JH, Maki G, Klingemann HG (1994) Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 8:652
67. Uherek C, Tonn T, Uherek B, Becker S, Schierle B, Klingemann H-G, Wels W (2002) Retargeting of natural killer-cell cytolytic activity of ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction. Blood 100:1265
68. Soliger B, Maurer MJ, Ferrone S (1997) TAPs off-tumors on. Immunol Today 18:292
69. Haynes NM, Snook MB, Trapani JA, Cerruti L, Jane SM, Smyth MJ, Darcy PK (2001) Redirecting mouse CTL against colon carcinoma superior signaling efficacy of single-chain variable domain chimeras containing TCR-ζ vs FcεRI-γ. J Immunol 166:182
70. Sadelain M, Riviera I, Breutjens R (2003) Targeting tumors with genetically enhanced T lymphocytes. Nat Rev Cancer 3:35
71. McGuinness RP, Ge Y, Patel SD, Kashmiri SVS, Lee HS, Hand PH, Schlom J, Finer MH, McArthur JG (1999) Antitumor activity of human T cells expressing the CC49-ζ chimeric immune receptor. Hum Gene Ther 10:165
72. Hwu P, Yang JC, Cowherd R, Treisman GE, Shafer Z, Eshhar Z, Rosenberg SA (1995) In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res 55:3369
73. Wang G, Ghopra RK, Royal RE, Yang JC, Rosenberg SA, Hwu P (1998) A T-cell independent antitumor response in mice with bone marrow cells retrovirally transduced with an antibody/Fc-gamma chain chimeric receptor gene recognizing a human ovarian cancer antigen. Nat Med 4:168
74. Brentjens R, Latouche JB, Riviere I, Sadelain K (2002) In vivo anti-tumor activity of genetically modified T cells is dependent on the method of ex vivo T cell expansion. Blood 100:577
75. Abken H, Hombach A, Reinold V, Ferrone S (1998) Can combined T cell and antibody based immunotherapy outsmart tumor cells? Immunol Today 19:2
76. Ren-Heidenreich L, Lum LG (2001) Life or death of T cells with antigen-specific receptors: using T cells for cancer adoptive immunotherapy/gene therapy. Curr Gene Ther 1(3):253-255
77. Patel SD, Moskalenko M, Smith D, Maske B, Finer MH, McArthur JG (1999) Impact of chimeric immune receptor extracellular protein domains on T cell function. Gene Ther 6:412
78. Hombach A, Schneider C, Sent D, Koch D, Willemsen RA, Diehl V, Kruis W, Bolhuis RL, Pohl C, Abken H (2000) An entirely humanized CD3 zeta-chain signaling receptor that directs peripheral blood T cells to specific lysis of carcinoembryonic antigen-positive tumor cells. Int J Cancer 88:120
79. Levey DL, Srivastava RK (1996) Alterations on T cells of cancer bearers: Whence specificity? Immunol Today 17:365
80. Zier K, Gansbacher B, Salvadori S (1996) Preventing abnormalities in signal transduction of T cells in cancer: the promise of cytokine gene therapy. Immunol Today 17:39
81. Gong MC, Latouche JB, Krause A, Heston WD, Bander NH, Sadelain M (1999) Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplasia 1:127
82. Rossig C, Bollard CM, Nuchtern JG, Rooney CM, Brenner MK (2002) Epstein-Barr virus-specific human T lymphocytes expressed antitumor chimeric T-cell receptors: potential for improved immunotherapy. Blood 99:2016
83. Daly T, Wang G, Li W, Herlyn D, Eshhar Z, Hwu P (2000) Recognition of human colon cancer by T cells transduced with a chimeric receptor gene. Cancer Gene Ther 7:291
84. Weijtens MEM, Hart EH, Bolhuis RL (2000) Functional balance between T cell chimeric receptor density and tumor associated antigen density: CTL mediated cytolysis and lymphokine production. Gene Ther 7:35
85. Krause A, Guo HF, Latouche JB, Tan C, Cheung NK, Sadelain M (1998) Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes. J Exp Med 188:626